PUBLISHER: Allied Market Research | PRODUCT CODE: 1396987
PUBLISHER: Allied Market Research | PRODUCT CODE: 1396987
The global multiplexed diagnostics market was valued at $10.7 billion in 2022, and is projected to reach $41.5 billion by 2032, growing at a CAGR of 14.5% from 2023 to 2032.Multiplexing is the process of simultaneously detecting or identifying multiple biomarkers in a single diagnostic test, which can be valuable for several different types of diseases. For instance, pharmacogenomic studies in patients with cardiovascular disease have indicated that the presence of polymorphisms affects response of a patient to various drugs. The multiplex detection of relevant biomarkers, hence, not only provides insight into the pathophysiology of cardiovascular disease, but also serves as a guide for the most efficient treatment option.
In addition, multiplex tests simultaneously analyze samples for multiple pathogens. Currently, available multiplex tests, including those from the life sciences company Thermo Fisher Scientific, leverage PCR techniques to selectively amplify genes specific to each virus of interest. For SARS-CoV-2, the test might amplify genes that code for the envelope protein (E gene) of the virus or the nucleocapsid protein (N gene). Targets may include virus specific matrix proteins as well as nucleocapsid proteins for Influenza A, B, and Respiratory syncytial virus (RSV), polymerase chain reaction (PCR).
Major factors that drive the growth of the global multiplexed diagnostics market include an increase in need for automated equipment and varied analytical methodologies, increase in incidence of disease outbreaks such as coronavirus and Ebola virus, and surge in technological innovations in assay design, detection methods, and data analysis techniques.
Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders are the major factors that increase the demand for multiplexed diagnostics tests kits and instruments and hence propel the growth of the market.
In addition, the increase in the number of key market players and the strategies they adopt for the development of technologically advanced multiplexed diagnostics products are the major factors that boost the growth of the multiplexed diagnostics market. For instance, in January 2023, Agilent Technologies, Inc. announced a partnership with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis and to commercialize workflow solutions for multiplex assays in the clinical research market. Integrating Dako Omnis (auto-staining instrument) of Agilent and PhenoImager HT (imaging platform) of Akoya for multiplex chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF) assays create a singular end-to-end commercial workflow, including reagents, staining, imaging, and analysis.
However, the high cost associated with multiplexed diagnostic assay, and lack of skilled professionals to operate diagnostic tools and conduct multiplexed diagnostic assay restrain the growth of the multiplexed diagnostics market. On the contrary, the surge in the demand for novel home health monitoring systems such as increase in demand for xPOCT devices, which ensure the quality and performance requirements of in vitro diagnostics, performed in a short period by non-experts and increased use of personalized medicine are expected to provide additional opportunities for the multiplexed diagnostics market to grow during the forecast period.
The multiplexed diagnostics market is segmented into product type, application, end user, and region. On the basis of product type, the market is bifurcated into instruments & accessories and kits & reagents. On the basis of application, it is segregated into infectious disease, oncology, autoimmune disease, cardiac disease, allergies, and others. On the basis of end user, it is segmented into hospitals, diagnostic centers, and others. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players profiled in the report are Co-Diagnostics, Inc. Agilent Technologies, Inc., bioMerieux SA, Illumina Inc., Hologic, Inc. Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., and DiaSorin S.p.A. The key players such as bioMerieux SA, Hologic, Inc. F. Hoffmann-La Roche Ltd., Agilent Technologies Inc, Bio-Rad Laboratories and DiaSorin S.p.A have adopted product launch, product approval, acquisition, and partnership as major developmental strategies to improve the product portfolio.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)